1836 U.S. Patent Office fire

United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation

Retrieved on: 
Monday, July 24, 2023
Legal, Biotechnology, Pharmaceutical, Health, FDA, Professional Services, Clinical Trials, Other Health, 1836 U.S. Patent Office fire, Patent, Intellectual property, IPR, Inhalation, United States Court of Appeals for the Federal Circuit, Marketing, PBC, PTAB, Federal, Associate, Creativity, Patent Trial and Appeal Board, Targanta Therapeutics Corporation, Patient, United Therapeutics, UTHR, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Generic drug, Pharmaceutical industry, United

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc.
  • The Federal Circuit affirmed that Liquidia’s proposed Yutrepia™ product infringes a United Therapeutics’ patent, U.S. Patent No.
  • The Federal Circuit also affirmed the district court’s decision that certain claims of another United Therapeutics patent, U.S. Patent No.
  • We will continue to vigorously defend our intellectual property,” said Shaun Snader, Vice President and Associate General Counsel – IP and Litigation at United Therapeutics.

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Retrieved on: 
Wednesday, July 19, 2023
1836 U.S. Patent Office fire, Patent, Intellectual property, Heart failure, Prevalence, United States Patent and Trademark Office, Coronavirus Scientific Advisory Board, IP, Patient, FDA, Therapy, Pulmonary hypertension, Pharmaceutical industry

The issued patent (U.S. Patent No.

Key Points: 
  • The issued patent (U.S. Patent No.
  • 11,701,355) covers the use of oral levosimendan for the treatment of PH-HFpEF and provides exclusivity through December 2040.
  • The ‘355 patent further builds upon the Company’s substantial IP, which also includes issued U.S. patents for the use of intravenous (U.S. Patent No.
  • This is the most commonly seen patient in pulmonary hypertension referral centers, and yet not a single therapy has been approved for them.

VennⓇ Secures Patent for First Technology to Make MDM for Laptops a Reality; Reveals $29 Million in Series A Funding led by NewSpring Capital

Retrieved on: 
Wednesday, June 28, 2023
1836 U.S. Patent Office fire, Workforce, Patent, Intellectual property, Partnership, Mobile device management, Bring your own device, United States Patent and Trademark Office, NewSpring Church, Mobile device, VDI, Computation, Investment, MDM, Growth, Entrepreneurship, BYOD, Blue, Online shopping, Video game, Venn

NEW YORK, June 28, 2023 /PRNewswire/ -- Venn Software, innovators of the first purpose-built technology for Secure BYO-PC, today announced that the company has been awarded a key patent for securing remote work on any computer. The company also revealed $29 Million in Series A Funding, led by NewSpring to support its product development, growth, and customer demand. Venn is the first company to deliver an MDM-like solution for laptops. MDM (Mobile Device Management) is frequently used by companies to protect sensitive company data on employees' personal phones. In similar fashion, Venn can now secure remote work on a laptop that is unmanaged or Bring Your Own Device (BYOD). Co-Founder and CEO, David Matalon, says, "It's a radically simplified and less costly new alternative to virtual desktop infrastructure (VDI)."

Key Points: 
  • The company also revealed $29 Million in Series A Funding, led by NewSpring to support its product development, growth, and customer demand.
  • In similar fashion, Venn can now secure remote work on a laptop that is unmanaged or Bring Your Own Device (BYOD).
  • Co-Founder and CEO, David Matalon, says, "It's a radically simplified and less costly new alternative to virtual desktop infrastructure (VDI)."
  • Through this work, it became clear that traditional VDI technology was not up for the challenge of an evolved workforce.

Pearl Granted Patent for Second Opinion® AI Software

Retrieved on: 
Thursday, June 22, 2023
Health, Technology, Health Technology, Software, Dental, Radiology, Artificial Intelligence, Patent, X-ray, System, API, Pathology, Second opinion, Dentist, Patient, 1836 U.S. Patent Office fire, AI, FDA, Second, Medical device, Medical imaging, Pearl

Pearl , the global leader in dental AI solutions, today announced that the United States Patent and Trademark Office has issued U.S Patent No.

Key Points: 
  • Pearl , the global leader in dental AI solutions, today announced that the United States Patent and Trademark Office has issued U.S Patent No.
  • This patent grants Pearl the exclusive rights to the computer system technology supporting the application programming interface (API) of its chairside AI disease detection software, Second Opinion ®.
  • With the most robust range of FDA-cleared clinical AI detection capabilities on the market, dental professionals using Second Opinion® AI can detect pathologies in x-rays with 37% more accuracy.
  • “This patent reflects the ingenuity at the core of our company and is a testament to our continued dedication to empowering dentists and patients with state-of-the-art technology.”
    This is the tenth patent granted for Pearl’s dental AI technology and the second covering Second Opinion®’s breakthrough technology.

Cecilian Partners Granted New U.S. Patent on Unique Anti-Monotony Software for Master Planned Communities

Retrieved on: 
Thursday, June 22, 2023
1836 U.S. Patent Office fire, XO, Patent, Communication, Property, Partner, HOPE

NEW HOPE, Pa., June 22, 2023 /PRNewswire/ -- Cecilian Partners, an award-winning proptech firm providing end-to-end digital solutions for homebuilders and land developers, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,537,964 covering its automated anti-monotony system for new home construction. A key feature of the company's signature technology platform, The XO, the anti-monotony system streamlines one of the most complex and costly processes in community development.

Key Points: 
  • A key feature of the company's signature technology platform, The XO, the anti-monotony system streamlines one of the most complex and costly processes in community development.
  • "The XO's anti-monotony system takes a process that's usually opaque and gives full transparency to both developer and builder," said John Cecilian, Jr., co-founder and CEO of Cecilian Partners.
  • "By making this process a seamless part of The XO, our software centralizes traffic, sales, and architectural reviews into one system, simplifying the entire process of new home construction for master planned communities."
  • Given the uniqueness and power of the anti-monotony solution, the patent was granted in less than eight months — record time for a software patent.

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Retrieved on: 
Wednesday, June 14, 2023
Carcinoma, Tissue, Pancreatic cancer, Patent, 1836 U.S. Patent Office fire, Index, Masonic Cancer Center, University, University of Minnesota, Aging Cell, Hepatocellular carcinoma, Cancer, Ageing, Inflammation, SASP, Cellular senescence, Regeneration, Colorectal cancer, Melanoma, Immune system, Ovarian cancer, Notifiable disease, Stomach, Phenotype, Fish & Richardson, Safety, Breast cancer, Wound healing, Vaccine, Pharmaceutical industry

The patent also includes methods of use claims for killing or reducing the number of senescent cells by administering HCW9218 in subjects with cancer.

Key Points: 
  • The patent also includes methods of use claims for killing or reducing the number of senescent cells by administering HCW9218 in subjects with cancer.
  • Senescence is considered a physiologic process that is important in promoting wound healing, regeneration, and many other vital functions.
  • The U.S. Patent and Trademark Office recognized the methods of treating cancer using the novel immunotherapeutic, HCW9218.
  • This method of use patent will support a previously issued patent, U.S. Patent No.

XRHealth Awarded Patent for Closed Loop Biofeedback for Therapy in Virtual Reality and Augmented Reality

Retrieved on: 
Wednesday, June 14, 2023
Cognition, Blood pressure, Patent, 1836 U.S. Patent Office fire, Motion, Patient, EEG, Pain management, Virtual reality, Apple, AI, Heart rate, XR, Health, Activator (genetics), Pharmaceutical industry, Medical imaging

BOSTON, June 14, 2023 /PRNewswire/ -- XRHealth, the leading spatial therapeutic platform, announces that they were awarded a patent for closed loop biofeedback for therapy in virtual reality and augmented reality. XRHealth's technology uses biometric and motion data to adjust training and treatment protocols, directly engaging with patients' responses to adjust and enhance therapy.

Key Points: 
  • BOSTON, June 14, 2023 /PRNewswire/ -- XRHealth , the leading spatial therapeutic platform, announces that they were awarded a patent for closed loop biofeedback for therapy in virtual reality and augmented reality.
  • The first use of this patent will be to combine the Apple watch with the new Apple Vision Pro to create a closed loop system to provide closed loop AI-based treatment.
  • In 2020, XRHealth was awarded a patent that enabled XRHealth to create XR-based therapy based on biofeedback that measured heart rate variability, EEG, galvanic skin response, and other critical responses to address pain management.
  • The patent was the first step in enabling XRHealth to leverage biofeedback to customize patient care.

Promosome LLC Sues Moderna, Pfizer, and BioNTech for COVID-19 Vaccine Patent Infringement

Retrieved on: 
Wednesday, June 7, 2023
Vaccine, 1836 U.S. Patent Office fire, BioNTech, Patent, CAB, JES, COVID-19, Messenger, Moderna, SAN, Scripps Research, Pharmaceutical industry, Pfizer

SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.

Key Points: 
  • SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.
  • The suits allege that the mRNA-based COVID-19 vaccines produced by these companies violate patented technology owned by Promosome.
  • While Moderna did not license the '179 Patent, mRNA sequence reverse engineering shows that Moderna took the patented technology for its vaccine, Spikevax®.
  • The second lawsuit, against Pfizer and BioNTech, alleges that Pfizer and BioNTech's joint COVID-19 vaccine Comirnaty® willfully infringes the '179 Patent.

BetFully Inc. Secures Yet Another U.S. Patent for Automated Lineup Optimization in Daily Fantasy Sports

Retrieved on: 
Friday, June 2, 2023
1836 U.S. Patent Office fire, Patent, Intellectual property, United States Patent and Trademark Office, Android, IOS, Algorithm, Sport, 3D printing, Amusement park

CARLSBAD, Calif., June 2, 2023 /PRNewswire-PRWeb/ -- BetFully Inc., a leading provider of cutting-edge technology solutions for the sports betting industry, is pleased to announce the grant of its latest patent, U.S. Patent No. 11,660,533, by the United States Patent and Trademark Office on May 30, 2023. This patent recognizes the company's groundbreaking innovation in the field of automated lineup optimizer for daily fantasy sports. This marks BetFully's fourth issued patent in the field of lineup optimization.

Key Points: 
  • 11,660,533 for their groundbreaking automated lineup optimization system in daily fantasy sports.
  • The patented lineup optimization technology is featured in BetFully's flagship product, LineStar, available on iOS, Android, and the web at LineStarApp.com.
  • This patent recognizes the company's groundbreaking innovation in the field of automated lineup optimizer for daily fantasy sports.
  • To learn more and access LineStar, visit LineStarApp.com
    "We are thrilled to receive this patent for our automated lineup optimization system," said Erik Groset, CEO of BetFully Inc.

GBT’s Database Management System, Continuation Patent Expected to be granted

Retrieved on: 
Wednesday, May 31, 2023
1836 U.S. Patent Office fire, Patent, GBT, Database, Internet of things, SAN, IP, OTC, Integrated circuit, Mobile phone, Information technology

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH ) ("GBT” or the “Company”), today announced that its continuation applications (U.S. Patent No. 11,663,167) for mobile database sharing will be granted. The database management patent protects a highly secured communication protocol and a method to produce increased processing of database objects through its networks. The continuation application enhances the scope and broadens the strength of the original patent. The technology seeks to improve to a great extent the weaknesses of known systems and methods of database management and sharing by providing an innovative method for database management and sharing over mobile devices, using a private, secured communication protocol. The invention’s methods and systems are based on GBT’s proprietary Integrated Circuit (IC) technology and a mobile/server software application to split database objects into segments and share them among other mobile devices. These segments are sent via private, secured channel to be stored on mobile devices worldwide and are indexed for restoration purposes. For restoration, the system collects all database segments from all devices worldwide and assembles them together to rebuild the database object. The patent’s protects a technology that aims to enable mobile and IoT devices to share and exchange vast amounts of data using highly secured, segmentation protocol. This protocol exponentially increases data security and integrity. The original non-provisional patent was granted on December 1, 2020, as a US patent #10,853,327. GBT plans to continue its R&D efforts in this domain with the aim of increasing cybersecurity measures of digital data.

Key Points: 
  • The continuation patent enhances the IP protection of secured, shared mobile database management system
    SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), today announced that its continuation applications (U.S. Patent No.
  • The database management patent protects a highly secured communication protocol and a method to produce increased processing of database objects through its networks.
  • For restoration, the system collects all database segments from all devices worldwide and assembles them together to rebuild the database object.
  • The original non-provisional patent was granted on December 1, 2020, as a US patent #10,853,327.